Trends in Single Cell Analysis #2: Tumor Cells
LifeScienceNet Düsseldorf
9/8/21, 7:00 PM
Europe/Madrid GMT+2
Description
Programme
Welcoming Speech
Dr. Thomas Heck, Life Science Center Düsseldorf
Prof. Dr. Nikolas Stoecklein, MD, Düsseldorf University Hospital
Academia
Moderation: Prof. Dr. Nikolas Stoecklein, MD, Düsseldorf University Hospital
The potential of analysing circulating tumor cells using diagnostic leukapheresis in prostate cancer patients
Martijn Lolkema, MD/PhD, Erasmus MC Cancer Institute in Rotterdam
Genomic and epi-genomic high-resolution profiling of single cells
Rui Neves, PhD, Düsseldorf University Hospital
A proof of concept study for the clinical use of circulating tumor cells
André Franken, PhD, Düsseldorf University Hospital
Companies
Moderation: Prof. Dr. Hans Neubauer, PhD, Düsseldorf University Hospital
Developments in single cell analysis and clinical utility
Tim Pitfield, Menarini Silicon Biosystems
Comprehensive profiling of tumor and their microenvironment by advanced single cell sequencing technologies
Nan Fang, PhD, MBA, Singleron Biotechnologies
Participation in the event is free of charge. You will receive the access data with the link to the meeting in a separate email.
Previous registration necessary?
NO
YES
Simultaneous translation ?
NO
YES
Will it be recorded?
NO
YES
Nikolas Stoecklein, Hans Neubauer
Welcoming Speech, The potential of analysing circulating tumor cells using diagnostic leukapheresis in prostate cancer patients, Genomic and epi-genomic high-resolution profiling of single cells, A proof of concept study for the clinical use of circulating tumor cells, Developments in single cell analysis and clinical utility, Comprehensive profiling of tumor and their microenvironment by advanced single cell sequencing technologies
Inglês
Speakers
Thomas Heck, Nikolas Stoecklein, Martijn Lolkema, Rui Neves, André Franken, Tim Pitfield, Nan Fang
Link to the Event
Banner to the Event

Register your event here
Already have an account? LOGIN HERE. If You don't have an account you need to create a free account.